Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tandem Diabetes Care reports robust sales growth and strategic innovations

Tandem Diabetes Care's strong financial performance, innovative product portfolio, and global market expansion efforts position it for continued growth and competitiveness.
While facing short-term challenges like seasonal EBITDA fluctuations and acquisition-related headwinds, Tandem's strategic focus on new product launches and market awareness presents opportunities for long-term success.
The company's emphasis on technology advancements, clinical initiatives, and leadership continuity underscores its commitment to driving innovation and meeting customer needs in the insulin therapy market.
With a clear roadmap for 2023, including revenue projections, margin expectations, and product development plans, Tandem is poised to navigate challenges and capitalize on growth opportunities in the evolving healthcare landscape.

Tandem Diabetes Care reports strong Q1 performance amidst competitive challenges

Tandem Diabetes Care's Q1 2023 earnings call showcased strong performance driven by product success and customer loyalty, despite challenges in international revenue and competitive landscape noise.
The company's focus on innovation, cost management, and product enhancements positions it well for long-term growth and market expansion, with opportunities in Libre integration and upcoming product launches.
While facing short-term challenges in Q2 revenue and margins, Tandem Diabetes Care remains confident in achieving its objectives through prudent cost management and commitment to product excellence.

Tandem Diabetes Care exceeds Q2 targets, eyes sustainable growth

Tandem Diabetes Care (TNDM) showcased strong Q2 performance, with a focus on sustainable growth and profitability. While facing challenges like market uncertainties, the company is leveraging opportunities through new product launches and cost efficiencies for future growth.

Tandem Diabetes Care surpasses Q3 sales expectations amidst market challenges

Tandem Diabetes Care's Q3 performance exceeded expectations with strong sales and positive margins, despite challenges in OUS distribution.
The company's focus on innovation, product success, and market positioning sets the stage for future growth opportunities.
Navigating disruptions and seizing growth potential through new product launches and market expansion are key priorities for Tandem.
Overall, Tandem remains optimistic about its trajectory and is actively pursuing strategic opportunities for growth.

Tandem Diabetes Care reports strong sales growth and strategic focus

Tandem Diabetes Care's Q4 2023 Earnings Call highlighted strong sales performance, positive customer feedback, and strategic focus on new product launches and operational efficiencies.
While facing challenges from unique events and increasing competition, Tandem is leveraging opportunities in U.S. and international markets, focusing on growth and innovation.
The company's outlook for 2024 includes a robust sales guidance, expansion plans, and a strategic approach to address market challenges and capitalize on emerging opportunities.

Tandem Diabetes Care reports robust Q1 sales growth and international expansion

Tandem Diabetes Care's Q1 2024 earnings call highlighted strong sales growth, successful product launches, and innovation in AID systems, with a focus on maintaining pricing and expanding internationally.
Challenges include pricing strategies, monitoring Mobi's impact, and navigating competitive OUS markets, while opportunities lie in market expansion, health outcome studies validation, and improving access and affordability.
Overall, Tandem's performance reflects a strategic approach to growth through product innovation, market expansion, and a focus on enhancing access and affordability in the diabetes care market.

Tandem Diabetes Care (TNDM) posts strong Q2 results, raises 2024 guidance

Tandem Diabetes Care (TNDM) reported robust Q2 2024 performance with sales growth, improved gross margin, and raised sales guidance. The company's focus on new products and commercial excellence positions it well for future growth.

Tandem Diabetes Care achieves record sales and positive cash flow

Tandem Diabetes Care delivered a strong performance in Q3 2024, marked by record sales and positive free cash flow. The company's focus on innovation, market awareness, and customer retention are key strengths. While facing challenges in a competitive market, Tandem Diabetes Care is well-positioned to capitalize on growth opportunities in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Inmode Ltd

Inspire Medical Systems Inc

Including some of these three top medical-device companies in your portfolio now could be savvy.

3 Fast-Growing Medtech Stocks to Buy

Eli Lilly

Provention Bio Inc

There are some highly promising diabetes treatments entering the market that investors should know about.

3 Top Diabetes Stocks to Watch in November

Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.

Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve

The insulin pump maker once again delivered stellar quarterly results.

How Tandem Diabetes Care Blew Past Wall Street Estimates in Q3

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q3 2019 Results - Earnings Call Transcript

Growth in t:slim X2 insulin pump sales is expected to get reflected in Tandem Diabetes' (TNDM) upcoming quarterly results.

What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?

Tandem (TNDM) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Tandem (TNDM) Catches Eye: Stock Jumps 9.5%

Tandem Diabetes (TNDM) gains on strong domestic sales along with a solid international rollout of the t:slim X2 insulin pump.

Tandem Rides on Strong t:slim X2 Rollout Amid Stiff Rivalry

The growth stock cooled off a bit last month but has still managed to scorch the market with a 51% year-to-date gain.

Here's Why Tandem Diabetes Care Fell 18.6% in September

Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).

Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds

Catalent

These two healthcare businesses are capturing formidable growth opportunities by executing in their overlooked niches.

2 Growth Stocks for In-the-Know Investors.

Tandem Diabetes Care has been struggling lately, but the selling pressure may be coming to an end soon.

Tandem Diabetes Care Sees Hammer Chart Pattern: Time to Buy?

Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.

Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ

Tandem's LTM pump shipments have nearly tripled, and LTM revenue more than doubled.

Tandem Diabetes: Bullish As Innovations Capitalize On A Booming Sector

The medical device company is cruising past everyone's expectations -- including its own.

Here's Why Tandem Diabetes Care Jumped 14.2% in August

Shockwave Medical

Wayfair

The dog days of summer are finally behind us (on the calendar, anyway), but these three stocks offer sizzling growth potential.

3 Top Growth Stocks to Buy in the Final Month of Summer

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

Abbott Labs

These three diabetes-oriented companies should be on your radar right now.

3 Top Diabetes Stocks to Watch in August

Crocs

CyberArk Software

Fortinet

Skechers U.S.A.

Inside the top-ranked stocks that can beat earnings estimates in their next release.

Beyond Earnings Growth: Focus on Beat With These 5 Stocks

EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (30-Year Financial, Insider Trades) Brian B Hansen (insider trades) sold 15,000 shares of TNDM on 08/12/2019 at an average price of $62.97 a share.

Tandem Diabetes Care Inc (TNDM) EVP & CHIEF COMMERCIAL OFFICER Brian B Hansen Sold $944,550.

Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.

Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark

The medical device company got oh-so-close to erasing operating losses in Q2, but second-half growth will finally put the business in the black.

Tandem Diabetes Care Raises Full-Year 2019 Revenue Guidance to $358 Million

Cross Country Healthcare

IAC/InterActiveCorp

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

5 Top-Ranked Stocks Primed for an Earnings Beat

The insulin pump maker trounced analysts' top- and bottom-line estimates on strong sales growth.

Tandem Diabetes Care Pumps Up Sales Dramatically in Q2

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q2 2019 Results - Earnings Call Transcript

News for Tandem Diabetes Care Stock (TNDM)